Whether durvalumab (durvalumab) has been included in medical insurance and the reimbursement policy in 2025

Durvalumab (Durvalumab) is currently on the market in China, but as of 2025 it has not yet been included in the national medical insurance directory, so patients using the drug in China are completely self-pay. Judging from public information, common specifications provided by domestic hospital pharmacies include 120mg/2.4mL and 500mg/10mL. The price per box is generally between more than 4,000 to more than 10,000 yuan. The specific price will fluctuate due to hospital procurement channels and regional differences. Since it is not covered by medical insurance, the cost burden is relatively heavy. Therefore, in clinical practice, it is mostly used by patients who have economic conditions or who have high expectations for efficacy.

In terms of medical insurance policies, the treatment area of durvalumab is mainly focused on immunotherapy of unresectable lung cancer and some solid tumors. Although its clinical value has been recognized by multiple guidelines, medical insurance negotiations usually require that the drug has a large enough domestic user population, clear efficacy and negotiable price. Because the price of this drug is still in a relatively expensive range, it has not yet been included in medical insurance. If prices are lowered in the future, market competition increases, or domestic alternatives increase, it is possible that imvalumab will be included in the medical insurance negotiation list. However, as of 2025 no official timetable for medical insurance access has been seen.

For patients who purchase drugs overseas, durvalumab is available as an original drug in countries such as Europe and the United States. Taking 120mg/2.4mL as an example, each box may cost more than a thousand US dollars. After converting according to the exchange rate, there is still a difference compared with the domestic price. Since there are currently no generic drugs on the market, the global market is dominated by original drugs. Therefore, if patients need to purchase medicines cross-border, they usually purchase them through Hong Kong, some overseas pharmacies, or entrust formal third-party platforms with legal prescriptions. However, they still need to pay attention to transportation, cold chain, and legal compliance issues.

Overall, the availability of durvalumab in China is still limited by price and medical insurance policies, and it is unlikely that the price will be significantly reduced or quickly included in medical insurance in the short term. If patients plan to use the drug for a long time, they should evaluate their affordability under the guidance of a doctor and rationally choose drug purchase channels to ensure that the source of the drug is regular, safe and reliable. At the same time, it is also recommended to pay attention to the subsequent updates to the drug catalog released by the National Medical Insurance Administration to learn if there are any new policy changes in a timely manner.

Keyword tags:

Durvalumab, PD-L1 inhibitors, medical insurance policy, 2025annual reimbursement, drug prices, self-paid drugs, overseas drug purchases

Reference materials:https://www.fda.gov/